The A-549 VIM RFP (ATCC® CCL-185EMT™) cell line harbors a C-terminal red fluorescent protein (RFP) tag on the vimentin gene. Vimentin has been implicated in many aspects of cancer initiation and progression, including epithelial-to-mesenchymal transition (EMT). Monitoring of RFP expression enables the tracking of the EMT status of cells in vitro and in vivo and provides researchers with a fluorescent and quantifiable readout tool to study EMT signaling pathways involved in cancer progression. This reported cell line is also ideal for high throughput (HTS) discovery and screening for new NSCLC EMT inhibitors.
|Date Created||10/12/2017 11:36 AM
|Date Updated||10/12/2017 11:36 AM